請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43540
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 曾宇鳳 | |
dc.contributor.author | Wen-Yi Kang | en |
dc.contributor.author | 康文譯 | zh_TW |
dc.date.accessioned | 2021-06-15T02:23:06Z | - |
dc.date.available | 2014-08-19 | |
dc.date.copyright | 2009-08-19 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-08-18 | |
dc.identifier.citation | 1. Weingart SN, Mc LWR, Gibberd RW, Harrison B. Epidemiology of medical error. West J Med. 2000; 172: 390-3.
2. Neale G, Woloshynowych M, Vincent C. Exploring the causes of adverse events in NHS hospital practice. J R Soc Med. 2001; 94: 322-30. 3. Santell JP, Hicks RW, McMeekin J, Cousins DD. Medication errors: experience of the United States Pharmacopeia (USP) MEDMARX reporting system. J Clin Pharmacol. 2003; 43: 760-7. 4. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol. 2006; 132: 277-85. 5. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 160S-98S. 6. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ. 2008; 179: 235-44. 7. Lee VW, You JH, Lee KK, Chau TS, Waye MM, Cheng G. Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients. J Thromb Thrombolysis. 2005; 20: 33-8. 8. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165: 1095-106. 9. Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother. 2005; 39: 1008-12. 10. Mori T, Asano M, Ohtake H, et al. Anticoagulant therapy after prosthetic valve replacement -optimal PT-INR in Japanese patients. Ann Thorac Cardiovasc Surg. 2002; 8: 83-7. 11. You JH, Chan FW, Wong RS, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol. 2005; 59: 582-7. 12. Chenhsu RY, Chiang SC, Chou MH, Lin MF. Long-term treatment with warfarin in Chinese population. Ann Pharmacother. 2000; 34: 1395-401. 13. Garg AX, Adhikari NK, McDonald H, et al. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes: a systematic review. JAMA. 2005; 293: 1223-38. 14. Tang PC, LaRosa MP, Newcomb C, Gorden SM. Measuring the effects of reminders for outpatient influenza immunizations at the point of clinical opportunity. J Am Med Inform Assoc. 1999; 6: 115-21. 15. Dexter PR, Perkins S, Overhage JM, Maharry K, Kohler RB, McDonald CJ. A computerized reminder system to increase the use of preventive care for hospitalized patients. N Engl J Med. 2001; 345: 965-70. 16. Fox J, Thomson R. Clinical decision support systems: a discussion of quality, safety and legal liability issues. Proc AMIA Symp. 2002; 265-9. 17. Cannon DS, Allen SN. A comparison of the effects of computer and manual reminders on compliance with a mental health clinical practice guideline. J Am Med Inform Assoc. 2000; 7: 196-203. 18. Weir CJ, Lees KR, MacWalter RS, et al. Cluster-randomized, controlled trial of computer-based decision support for selecting long-term anti-thrombotic therapy after acute ischaemic stroke. QJM. 2003; 96: 143-53. 19. Fitzmaurice DA, Hobbs FD, Murray ET, Holder RL, Allan TF, Rose PE. Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial. Arch Intern Med. 2000; 160: 2343-8. 20. Chen WC. A preliminary study of clinician satisfaction on hospital high risk reminding system-a medical center case report. Taiwan; 2006. 21. Ammenwerth E, Schnell-Inderst P, Machan C, Siebert U. The Effect of Electronic Prescribing on Medication Errors and Adverse Drug Events: A Systematic Review. J Am Med Inform Assoc. 2008; 15: 585-600. 22. Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005; 352: 969-77. 23. Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG. Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment). Haematologica. 2001; 86: 1060-70. 24. Paterno MD, Maviglia SM, Gorman PN, et al. Tiering drug-drug interaction alerts by severity increases compliance rates. J Am Med Inform Assoc. 2009; 16: 40-6. 25. National Center for Health Statistics CfMMS. The International Classification of Diseases, 9th Revision, Clinical Modification. 2009 [cited; Available from: http://icd9cm.chrisendres.com/icd9cm/. 26. Department of Health, Executive Tuan, R.O.C. (Taiwan). The Information of Health Care Personnel in Practice. 2009 [cited; Available from: http://www.doh.gov.tw/Medical_Personnel/. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/43540 | - |
dc.description.abstract | 華法林 (warfarin) 是一種常見的的口服抗凝血劑,用來預防及治療與凝血機制相關疾病。而此藥的療效是不容易被控制,會受很多干擾因子影響,像病患本身的體質、飲食習慣、同時併用的藥物等等,都會使得華法林的療效不穩定。過多的劑量會增加發生出血併發症的危險,過少的劑量則有可能會導致栓塞。因此醫生抽血檢驗凝血酶原時間 (PT) ,來監測華法林的藥效,確保病人的療效是在安全範圍之內。為了使各地醫院治療目標一致,將凝血酶原時間轉換為國際標準化比值 (INR) ,一般認為白種人的華法林療效範圍約在INR值2-3之間,但是對於亞洲人而言,較低劑量是相對比較安全的,出現嚴重的併發症的比例較低。
我們擷取在2006年1月1日至2008年12月31日間,曾在台大醫院門診服用華法林的病患資料。全部共有4794位病患被納入分析,他們的平均INR值為2.00 ± 1.20,出血及栓塞事件的發生率為每病人年6.1%。 臺大醫院檢驗醫學部設有危急值警示系統,用來監測INR值是否超過安全值,當PT > 50時,則檢驗醫學部人員會打電話通知醫生,告知有病患的INR值超過安全範圍。檢驗醫學部在2007年5月17日建立PHS危急值警示系統,改用傳簡訊的方式通知醫生,取代原有的打電話方式。我們將2006年1月1日至2007年5月16日訂為人工通報時期,而將PHS通報時期訂為2007年9月1日至2008年12月31日。利用兩個時期的比較,我們評估改用PHS危急值警示系統之後,華法林的併發症發生率是否有升高,和醫生對於通報處理的比較。我們考慮了併發症發生率與季節相關,將兩組的追蹤時段各取一『日曆年』來做比較,另外也對於不同科別及醫生年資分別做探討。我們的結果顯示,醫生對於危急值的處理,和病人的出血及栓塞事件發生率,並沒有因改為PHS危急值警示系統而改變,甚至對於資深醫師醫療行為有提升的作用。 根據我們的研究,台灣病患服用華法林的劑量不宜太高。另外,在監測華法林的療效上,傳簡訊通知醫師的效果與打電話告知差異不大,病人發生併發症情況及醫師的醫療行為在二種警示系統上並沒有明顯改變;對於資深醫師,傳簡訊的方式較能增進醫療的品質。所以,PHS危急值警示系統是適合用在實驗室危急值的通報上。 | zh_TW |
dc.description.abstract | Warfarin is a common oral anticoagulant that prescribed for the management of thromboembolic disorders. It has narrow therapeutic range, and its therapeutic effect was varied due to multiple factors such as a patient’s physical condition, diet habits, and concurrently used medicines etc. Higher dosage of warfarin may increase the risk of bleeding, but lower dosage may lead to thromboembolism. Therefore, clinicians monitored warfarin effect with prothrombin time (PT) tests and standardized international normalized ratio (INR) to ensure patients’ safety and effectiveness. In general, a recommendation of a therapeutic INR value of 2 to 3 was made for most indications for Caucasians, but a lower dosage of warfarin treatment might be appropriate for Asians.
We included relevant records of outpatients receiving warfarin at National Taiwan University Hospital (NTUH) from January1st, 2006 to December 31st, 2008. In this study, a total of 4794 outpatients were included, and the mean INR values of them were 2.00 ± 1.20. The incidence rate of adverse drug events was 6.1% per patient-year. A PHS alert system for high PT/INR threshold values (PT > 50 seconds) has been established since May 17th, 2007 in NTUH. We defined January 1st, 2006 to May 16th, 2007 as the manual reminders period, and starting from September 1st, 2007 to December 31st, 2008 as the PHS alert system period. We assessed the impact of the new PHS alert system by comparing practitioner performance and patient outcomes between manual reminders and PHS periods. Adverse drug events in one calendar year were also analyzed between 2 groups considering seasonal effect. Physician specialty and seniority were took into account when practitioner performance was evaluated. Lower dosage of warfarin treatment might be considered as appropriate for patients in Taiwan. A switch to PHS alert system from manual reminders did not compromise patient outcomes and clinician performance, and indeed improved quality of care in senior physicians. PHS alert system was promising as a reminder of laboratory alert values to clinicians. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T02:23:06Z (GMT). No. of bitstreams: 1 ntu-98-R96945038-1.pdf: 1355888 bytes, checksum: 31fbbac8d1a5bc438ced8bd94337d867 (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 致謝 II
中文摘要 i Abstract iii Contents v List of figure x List of Table xii Chapter 1 Backgrounds and Literature Review 1 1.1 Introduction 1 1.2 Motivation 2 1.3 Literature Review 2 1.3.1 Anticoagulation therapy with warfarin 2 1.3.2 The INR range of warfarin therapy in Chinese population 5 1.3.3 Computerized clinical decision support systems in hospital settings 7 1.3.4 Electronic prescribing on medication errors and adverse drug events 18 1.4 Aim 25 Chapter 2 Materials and Methods 26 2.1 Materials 26 2.1.1 Study population and relevant data for study 26 2.1.2 Warfarin prescriptions 27 2.1.3 PT/INR measurement records 27 2.1.4 Warfarin complications and operation records 28 2.2 Methods 28 2.2.1 Data collection and follow-up duration 28 2.2.2 Patients profiles 29 2.2.3 Warfarin prescriptions analysis 31 2.2.4 PT/INR measurement assessment 32 2.2.5 Prevalence of severe complication events of warfarin 33 2.2.6 Evaluation of PHS alert system 35 Chapter 3 Results 37 3.1 The warfarin therapy in National Taiwan University Hospital from January 1st, 2006 to December 31st, 2008 37 3.1.1 Demographics of patient receiving warfarin in NTUH 37 3.1.2 Warfarin prescribing pattern 38 3.1.3 Dosage and PT/INR 39 3.1.4 Characteristics of warfarin complication 44 3.1.5 Practitioner Reaction at Different Departments when PT Values greater than 50 seconds 50 3.1.6 The impact of physician seniority on his/her reaction when PT Values greater than 50 seconds 52 3.2 Evaluation of Personal Handy-phone System generated reminders in NTUH from January 1st, 2006 to May 16st, 2007 (16.5 months) and from September 1st, 2007 to December 31st, 2008 (16 months) 55 3.2.1 Demographics profile 55 3.2.2 Warfarin dosage and PT/INR 56 3.2.3 Complication of warfarin use 59 3.2.4 Clinicians’ performance 60 3.2.5 Clinicians’ performance in different departments 62 3.2.6 Clinicians’ performance in senior and junior physicians 64 3.3 Evaluation of Personal Handy-phone System generated reminders in NTUH from January 1st, 2006 to December 31st, 2006 and from January 1st, 2008 to December 31st, 2008 (1 year) 67 3.3.1 Demographics profile 67 3.3.2 Warfarin dosage and PT/INR 68 3.3.3 Complication of warfarin use 71 3.3.4 Clinicians’ performance 72 3.3.5 Clinicians’ performance in different departments 74 3.3.6 Clinicians’ performance in senior and junior physicians 76 Chapter 4 Discussion 79 4.1 Demographics profile of patient treated with warfarin in NTUH 79 4.2 Dosage and PT/INR profile in NTUH 79 4.3 Incidence rate of complications related to warfarin use 81 4.4 Impact of PHS alert system switching 82 4.5 Evaluation of PHS alert system switching at NTUH 84 4.5.1 Advantage and disadvantage 84 4.5.2 Possible Improvement 85 4.6 Limitations 86 Chapter 5 Conclusion 88 Reference 89 | |
dc.language.iso | en | |
dc.title | 不同PT/INR危急值警示系統與warfarin使用安全性之評估 | zh_TW |
dc.title | Impact of Personal Handy-phone System (PHS) Reminder System on Practitioner Performance and Patient Outcomes in Warfarin Users | en |
dc.type | Thesis | |
dc.date.schoolyear | 97-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 林淑文 | |
dc.contributor.oralexamcommittee | 林東燦,陳俊良,林香汶 | |
dc.subject.keyword | 抗凝血劑,華法林,危急值警示系統,PHS通報系統,系統比較, | zh_TW |
dc.subject.keyword | warfarin,international normalized ratio (INR),adverse drug event (ADE),reminder system,PHS alert system, | en |
dc.relation.page | 92 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2009-08-18 | |
dc.contributor.author-college | 電機資訊學院 | zh_TW |
dc.contributor.author-dept | 生醫電子與資訊學研究所 | zh_TW |
顯示於系所單位: | 生醫電子與資訊學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf 目前未授權公開取用 | 1.32 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。